

September 22, 2016

# BD Invests \$100 Million In Nebraska Plant To Expand Insulin Syringe Manufacturing

FRANKLIN LAKES, N.J., Sept. 22, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it is investing \$100 million in its Holdrege, Neb. facility to expand capacity for its insulin syringe manufacturing operations.

The investment will be used for new technology and manufacturing equipment to expand capacity for BD insulin syringes. BD already produces more than 2 billion insulin syringes each year, which averages to be more than 250,000 syringes per hour.

"About 40 percent of people with diabetes who inject insulin use syringes as part of their diabetes management regimen," said Ken Miller, worldwide president of Diabetes Care for BD. "This investment will provide benefits to this diabetes population and underscores our commitment to supply high-quality, industry-leading insulin syringes to patients."

BD began operations in Holdrege in 1966 in a 12,000 square foot building with 66 associates. Today, the facility has grown to 350,000 square feet with more than 650 associates manufacturing 20 different BD products. BD is the largest employer in Phelps County. Across Nebraska, BD employs more than 2,500 associates in four manufacturing facilities in Holdrege, Broken Bow and two in Columbus.

## About BD

BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, optimize respiratory care and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 45,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health. For more information on BD, please visit [bd.com](http://bd.com).

### Contacts:

Troy Kirkpatrick  
BD Public Relations  
858.617.2361  
[troy.kirkpatrick@bd.com](mailto:troy.kirkpatrick@bd.com)

Monique N. Dolecki  
BD Investor Relations  
201.847.5378  
[monique\\_dolecki@bd.com](mailto:monique_dolecki@bd.com)

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/bd-invests-100-million-in-nebraska-plant-to-expand-insulin-syringe-manufacturing-300332348.html>

SOURCE BD (Becton, Dickinson and Company)